WO1999031237A1 - Facteur inhibiteur de l'apoptose - Google Patents

Facteur inhibiteur de l'apoptose Download PDF

Info

Publication number
WO1999031237A1
WO1999031237A1 PCT/JP1998/005609 JP9805609W WO9931237A1 WO 1999031237 A1 WO1999031237 A1 WO 1999031237A1 JP 9805609 W JP9805609 W JP 9805609W WO 9931237 A1 WO9931237 A1 WO 9931237A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
protein
acid sequence
cells
cell death
Prior art date
Application number
PCT/JP1998/005609
Other languages
English (en)
Japanese (ja)
Inventor
Yasuo Uchiyama
Yoshiyuki Ohsawa
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to AU15063/99A priority Critical patent/AU1506399A/en
Publication of WO1999031237A1 publication Critical patent/WO1999031237A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins

Definitions

  • the present invention relates to a factor having an activity of suppressing cell death (cell death suppressing factor, hereinafter referred to as PCTF35), a gene encoding the same, and a pharmaceutical use thereof.
  • PCTF35 cell death suppressing factor
  • Many neurodegenerative diseases are said to cause neurons to die and develop due to abnormalities in nerve cells or signal transmission between nerve cells.
  • Parkinson's disease is said to be caused by the degeneration of the substantia nigra neurons and the cessation of production of dopamine, one of the neurotransmitters, and the death of dopaminergic neurons.
  • Alzheimer's disease is said to cause dementia mainly due to death of neurons in the cerebral cortex and hippocampus.
  • Identification of a protein that suppresses nerve cell death which is thought to be the cause of neurological disease, or that promotes nerve cell growth, and the gene that encodes it, will provide an effective therapeutic agent for diseases caused by nerve cell death. It can be provided, and is extremely important in searching for compounds that mimic it. That is, a protein having an activity of suppressing the death of nerve cells can itself be an effective medicine, and at the same time, has a substance having a function similar to that of the protein, and has an action of inhibiting or promoting the function. It is also very useful when developing substances as drugs. Disclosure of the invention
  • the present inventors have focused on the b C 2 gene suppresses cell death, assuming inducible expression of proteins involved in curbing cell death, Toko filtrate was examined for the presence of such protein, By introducing the b2 gene, it was found that a factor (PCT F35) having the activity of suppressing cell death was secreted out of the transformed cells. Then, the PCTF 35 was purified and isolated, and further, based on the purified partial amino acid sequence of PCTF 35, the gene encoding the same (hereinafter referred to as pctf 35) was cloned, and the present invention was carried out. completed.
  • PCT F35 a factor having the activity of suppressing cell death
  • the present invention relates to a protein comprising the amino acid sequence of SEQ ID NO: 1 or a sequence comprising the amino acid sequence of SEQ ID NO: 1 in which one or several amino acids have been deleted, replaced or added. It is a protein that has the activity of inhibiting cell death.
  • the present invention relates to a gene encoding a protein comprising the amino acid sequence of SEQ ID NO: 1.
  • the present invention relates to a DNA comprising the nucleotide sequence of SEQ ID NO: 2, or a protein that hybridizes with the DNA of SEQ ID NO: 2 under stringent conditions and has an activity of suppressing cell death.
  • the DNA to be loaded is the nucleotide sequence of SEQ ID NO: 2, or a protein that hybridizes with the DNA of SEQ ID NO: 2 under stringent conditions and has an activity of suppressing cell death.
  • the present invention relates to a cell death inhibitory factor characterized by being a proteinaceous substance having the following physicochemical properties and physiological activities (1) to (4).
  • amino acid sequence from the 1st to 22nd amino acid on the N-terminal side is the following amino acid sequence; Va1etG1ySerG1yAspSperVa1
  • amino acid sequence at the N-terminal 1 38 to 14 1 is the following amino acid sequence Ty r A rg G ly A rg
  • the present invention is a pharmaceutical composition for suppressing cell death, comprising the protein or the cell death inhibitor as an active ingredient.
  • FIG. 1 is a photograph showing the morphology of an organism, showing wild type PC12 cells in a growing state (the cell density is 2500 cells).
  • Figure 2 is a photograph showing the form of the biologically, wild-type PC 1 2 cells (cell density 2 500. 1 11 2) after 24 hours was shifted to serum-free medium, killing conditions 1 shows wild-type PC12 cells.
  • Figure 3 is a photograph showing the morphology of the organism. Wild-type PC12 cells (cell density of 2500 cells ⁇ 1112) were transferred to a serum-free medium containing the culture supernatant of PC12bc2 cells. The figure shows wild-type PC12 cells 24 hours after the transfer.
  • FIG. 4 shows a reversed-phase chromatograph of a culture supernatant of PC12 / bc £ 2 cells using 60% acetonitrile containing 0.05% of choline as a gradient solvent.
  • % NGF cell death suppressing activity
  • the longitudinal axis right and line shows the solvent gradient (Asetonitoriru concentration. / 0).
  • FIG. 5 is a photograph showing the results of electrophoresis, and shows a gel stained with silver after fractionation 11 obtained by reverse phase chromatography was subjected to SDS-PAGE.
  • Figure 6 is a photograph showing the results of electrophoresis.
  • the fraction 11 obtained by reversed-phase chromatography was subjected to Natent-PAGE, followed by CBB-stained gel and the position of the confirmed protein. Or — as shown in 4.
  • FIG. 7 shows the cell death inhibitory activities of the proteins corresponding to -1 to -4 in FIG. 6 (the vertical axis represents% activity).
  • FIG. 8 is a photograph showing the result of electrophoresis, and is a diagram of a gel of a protein corresponding to -1 in FIG. 6 in which cell death inhibitory activity was confirmed, which was subjected to silver staining after SDS-PAGE.
  • FIG. 9 shows the N-terminal amino acid sequence of PCTF35 determined by the amino acid sequencer. In the figure? Means an unidentified residue.
  • FIG. 10 shows the amino acid sequence at the N-terminus of a 28 kd protein, which is a limited digest of PCTF 35, determined by the amino acid sequencer.
  • FIG. 11 is a photograph showing the results of electrophoresis and shows the results of exposure of Northern hybridization to mRNA extracted from a transformant containing the gene pctf35. Lanes 1 to 3 show each clone of PCI 2Zp CTF cells, lane 4 shows PC12 / pc DNA3 cells, and lane 5 shows wild-type PC12 cells.
  • FIG. 12 shows the survival rate of PC 12 / p CTF cells in serum-free medium.
  • the present inventors transduced the b2 gene into rat PC12 cells, which are pheochromocytomas, and analyzed the transformed cells (hereinafter referred to as PC12Zbc2 cells) for functional analysis of the b2 gene.
  • PC12Zbc2 cells transformed cells
  • Wild-type PC12 cells will die if serum is removed from a suitable growth medium. However, PC12 / bc2 cells transformed with the b2 gene continued to grow without cell death even in a serum-free medium, and exhibited the behavior of extending projections.
  • the present inventors have paid attention to the behavior of the PC12 / b2 cells and assumed that a factor having an activity of suppressing cell death may be secreted out of the cells. Therefore, a culture supernatant was prepared after culturing PC 12Zb c £ 2 cells, and this was added to a serum-free medium, that is, wild-type PC 12 placed in an environment where the cells died. It was confirmed that the wild-type PC12 continued to grow similarly to the PC12 / b2 cells, and extended the protrusion. This is, PC 12Zb C f 2 cells, showing that the releasing agent having activity of inhibiting the death of the other PC I 2 cells culture ground.
  • the present inventors investigated the factors that suppress cell death, which are thought to be present in this medium, by using reversed-phase high-performance liquid chromatography (RP-HPLC) using 60% acetonitrile as a developing solvent, and polyacrylamide electrophoresis. (PAGE) was used for purification. As a result, a protein having a molecular weight of 35 kDa in SDS-PAGE could be recovered. By confirming that the recovered protein had an activity to suppress cell death, it was determined that the protein was the target cell death inhibitory factor, that is, PCTF35.
  • RP-HPLC reversed-phase high-performance liquid chromatography
  • PCTF35 target cell death inhibitory factor
  • the present inventors have studied the N-terminal 21 residues of PCTF35 purified by the above method. , And the N-terminal amino acid sequence of the limited digest obtained by cutting the peptide chain of PCTF 35 with Bromcian were analyzed (FIGS. 9 and 10). Oligonucleotides consisting of the deduced nucleotide sequence were synthesized based on these amino acid sequences, and messenger RNA (mRNA) prepared from PC12 cells by the polymerase chain reaction (PCR) method using this as a probe. From the cDNA library prepared from the above, the gene pctf35 encoding PCTF35 could be cloned.
  • mRNA messenger RNA
  • the gene pctf35 corresponds to a region encoding a PCTF35 consisting of a total of 256 amino acid residues including a signal peptide in the 1645 base pair (bp) base sequence shown in SEQ ID NO: 3.
  • PCTF35 of the present invention is a secreted protein secreted extracellularly by a sidanal peptide consisting of 23 amino acid residues.
  • This secreted PCTF 35 is a protein with an estimated molecular weight of 24.9 kd consisting of 233 amino acid residues.According to the measurement of the molecular weight by SDS_PAGE, the molecular weight of secreted PCTF 35 is 35 kd. Therefore, it is considered that PCTF35 has undergone some modification such as a sugar chain.
  • PCTF 35 of the present invention to suppress cell death means that when PCTF 35 is added to cells, the cells continue to grow without being killed even in the absence of NGF and serum. Means that. When acted on PC12 cells, PCTF35 of the present invention exhibits an activity of suppressing cell death and an activity of promoting extension of projections.
  • wild-type PC12 cells were prepared from serum or NGF (Nurve
  • Such activity of PCTF 35 to suppress cell death can be confirmed by observing cell survival.
  • a simple method for measuring the activity of NGF which exhibits cell death-inhibiting activity similar to PCTF35 (Sasaki et al., Abstracts of the 4th Annual Meeting of the Japan Society for Alternatives to Animal Experiments, 1990, According to p. 85)
  • LDH lactate dehydrogenase
  • PCTF 35 which is a protein that suppresses cell death
  • PCTF 35 and the gene encoding it, Pctf 35 are extremely useful in developing a substance having a function similar to that of the protein, a substance having an action of inhibiting or promoting the function, or the like as a medicine.
  • the gene pctf35 is indispensable for mass-producing PCTF35 using genetic recombination technology and the like.
  • any gene that encodes a protein having the amino acid sequence shown in SEQ ID NO: 1 is within the scope of the present invention.
  • a DNA that hybridizes with the DNA and encodes a bioactive protein having an activity of suppressing cell death is also included in the scope of the present invention. ⁇ .
  • the full-length sequence of the gene pctf35 is partially modified by various artificial treatments, for example, site-directed mutagenesis, random mutation by treatment with a mutagen, and mutation / deletion / ligation of DNA fragments by restriction enzyme cleavage. Even if the DNA sequence is changed, it is a DNA that hybridizes with the gene pctf35 under stringent conditions and encodes a bioactive protein having cell death inhibitory activity, even if the DNA sequence is changed. Irrespective of the difference from the DNA sequence shown in SEQ ID NO: 2 Are within the range.
  • the degree of the above-mentioned DNA mutation is 90 ° / 90 ° with the DNA sequence of the gene pctf35.
  • a substance having the above homology is acceptable.
  • the degree of hybridization with the gene P ctf 35 can be determined under normal conditions (for example, when the probe is labeled with DIG DNA Labeling kit (Cat No. 1175033 manufactured by Boehringer Mannheim) at 32 ° C). In DIGE asy Hy b solution (Berlinger's Mannheim Co., Cat No.
  • the mutant is a protein having cell death inhibitory activity.
  • Variants are within the scope of the present invention.
  • the side chains of the amino acids that are the constituents of proteins differ in hydrophobicity, charge, size, etc., but do not substantially affect the three-dimensional structure (also called three-dimensional structure) of the entire protein In this sense, some highly conservative relationships are known empirically and by physicochemical measurements.
  • substitutions, insertions, and substitutions in the amino acid sequence of PCTF 35 shown in SEQ ID NO: 1 Even if it is a mutant protein due to deletion or the like, the mutation is a highly conserved mutation in the three-dimensional structure of PCTF 35, and the mutant protein has a cell death inhibitory activity like PCTF 35 If so, they can be said to be within the scope of the present invention.
  • the degree of mutation is within a range in which homology with the amino acid sequence shown in SEQ ID NO: 1 is 90% or more.
  • Examples of such a mutant protein include a protein consisting of an amino acid sequence obtained by removing the amino acid sequence corresponding to the fern peptide from the amino acid sequence shown in SEQ ID NO: 4.
  • the amino acid sequence shown in SEQ ID NO: 4 was obtained as follows. That is, as a result of searching a human fetal brain cDNA library using a part of the gene shown in SEQ ID NO: 3 as a probe, a sequence having high homology to the gene shown in SEQ ID NO: 2 was obtained. A gene which is considered to encode a human-derived cell death inhibitory factor shown in No. 5 was obtained.
  • the amino acid sequence shown in SEQ ID NO: 4 was obtained from the nucleotide sequence of this gene, and a protein having the amino acid sequence of this amino acid sequence excluding the amino acid sequence corresponding to the signal peptide was obtained.
  • PCTF 35 of the present invention can be produced in a medium by culturing rat PC12 cells transformed with the b2 gene in an appropriate medium.
  • the bc2 gene is recombined into a shuttle vector that can be replicated and maintained in both PC12 cells and Escherichia coli or Bacillus subtilis, such as pcDNA3, pAGE123, etc. It can be introduced into PC12 cells by a general gene transfer method such as the Yong method.
  • the transformed PC12 / bc £ 2 cells may be cultured in an appropriate medium such as RPMI1640 medium or HDMEM medium, and require no special culture method or means. do not do.
  • the PCTF 35 of the present invention is prepared by linking the gene pctf 35 of the present invention to a vector for recombination by a general gene recombination technique to prepare a recombinant gene pctf 35, It can also be produced by expression in a single host vector system.
  • a suitable vector is a plasmid derived from E. coli (eg, pBR32, pUCll8, etc., Bacillus subtilis-derived plasmids (eg, pUB110, pC194, etc.), yeast-derived plasmids (eg, pSH19, etc.), and more Animal viruses such as bacteriophage II retrovirus and vaccinia virus can be used.
  • an appropriate expression promoter can be connected upstream of the gene.
  • the promoter to be used may be appropriately selected depending on the host. For example, when the host is Escherichia coli, a T7 promoter, a lac promoter, a trp promoter, a p-promoter, etc., and when the host is a Bacillus genus, an SPO-based promoter, etc.
  • the host is a yeast, a PHO5 promoter, a GAP promoter, an ADH promoter, or the like can be used.
  • an SV40-derived promoter, a retrovirus promoter, or the like can be used.
  • the PCTF35 of the present invention can also be expressed as a so-called fusion protein by linking the gene pctf35 to a gene encoding another protein (eg, glutathione S transferase, protein A, etc.). It is possible.
  • the fused PCTF35 expressed in this manner can be excised using an appropriate protease (eg, thrombin or the like).
  • Examples of the host that can be used for expression of the PCTF 35 of the present invention include various strains of Escherichiaco 1 i that is a genus Escherichia, various strains of Bacillus aci 1 1 uss ⁇ bti 1 is, and yeasts.
  • Various strains of S accharo my cescerevisiae and animal cells include COS-7 cells, CHO cells, PC12 cells and the like.
  • a transformation method generally used in accordance with the host cells to be used such as a calcium chloride method or an electroporation method, can be applied. it can.
  • the protein of the present invention for example, a protein consisting of the amino acid sequence shown in SEQ ID NO: 1 or a mutant protein thereof, for example, the amino acid sequence shown in SEQ ID NO: 4 excluding the amino acid sequence corresponding to the signal peptide, Proteins consisting of amino acids It is useful as a drug that suppresses For example, it can be specifically applied to the treatment of diseases related to nerve cell death, such as Parkinson's disease and Alzheimer's disease.
  • the protein of the present invention can be prepared as a lyophilized product by a conventional method and applied to humans, for example, as an injection.
  • the dose may vary depending on the subject to be applied, the administration route and the like, but is usually from lg to l001718 / body weight 1 ⁇ g ⁇ day.
  • PC12 cells were cultured in a 6-well plate containing HDMEM medium for 24 hours, and then 1.5 ⁇ g of the expression vector pAGE123 obtained by recombining the human b2 gene was added, followed by the calcium phosphate method.
  • Marker substance G4 18 (Wako Pure Chemical Industries) 4 PC12 cells transformed with pAGE123 containing gene bc (2 by culturing for 14 days in HDMEM medium containing 50 g mL ( PCl SZb cf Z cells) were prepared.
  • the cell death inhibitory activity of PCTF35 of the present invention was measured according to the method of Sasaki et al. (Described above), and the lactate deoxygenase in wild-type PC12 cells when PCTF35 was allowed to act on wild-type PC12 cells.
  • the method for measuring the activity of the drogenase (LDH) was specifically measured by the following procedure.
  • a sample containing PCTF 35 was lyophilized and then dissolved in HDMEM medium to obtain a test sample.
  • prepared HDMEM media 200 mu L containing about 5000 wild-type PC 1 2 cells there was added a test sample 200 mu 1, C0 2 cell culture vessel For 24 hours. After the culture, each sample was collected in an Etbendorf tube, and wild-type PC12 cells were spun down and collected at 3000 X g for 5 minutes. After washing the collected PC12 cells with physiological saline (PBS) adjusted to pH 6.8 with phosphate buffer, the PC12 cells were solubilized with PBS containing 0.2% Tween.
  • PBS physiological saline
  • the eluted LDH activity was measured using MTX "LDH” (manufactured by Kyokuto Pharmaceutical).
  • LDH low density lipoprotein
  • PC12 cells were also measured and set as a standard value, and the ratio (% NGF) to the standard value was calculated.
  • the cell death inhibitory activity of PCTF 35 contained in the test sample was determined.
  • the fraction 11 obtained in a) was freeze-dried and then dissolved in 100 L of 20 mM Tris-HCl buffer (pH 8.0). Add 4 ⁇ L of 5X sampling buffer to 16 ⁇ L of this dissolved sample, and heat for 5 minutes in boiling water to denature the sample. Perform SDS-PAGE under the following conditions, and fractionate The molecular weight of the protein contained in 11 was measured.
  • Running buffer 25 mM Tris, 0.192 M glycine, 0.1% SDS Electrophoresis conditions; Concentrated gel 50 V, Separation gel 150 V
  • the gel after electrophoresis was stained with Coomassie Blue (CBB) and the presence of protein was confirmed by the blue band.
  • the protein with the highest content in the recovered fraction was confirmed to have a molecular weight of 35 kd. Was done.
  • the gel after this CBB staining is shown in FIG.
  • Nativ e-PAGE was performed under the following conditions. Concentrated gel; l mL 12.5% T—2% C acrylamide solution
  • Running buffer 25 mM Tris, 0.192 M glycine
  • the excised gel is immersed in 200 // L 20 mM Tris buffer solution, pH 8.0 for 24 hours at 4 ° C to extract the protein in the gel, and the gel is centrifuged to recover the supernatant. did.
  • Each of the collected supernatants was dialyzed against HDMEM medium for 12 hours at 4 ° C., and the cell death inhibitory activity of each sample was confirmed. As a result, this activity was observed in the protein recovered from the gel corresponding to -1.
  • PC TF 35 located at 35 kd was transferred from immobilized gel to Immobilon P SQ membrane (Millipore) with 10 mM methanol containing 10% methanol. Using PS (pH 11) buffer, transcription was performed at 18 OmA for 90 minutes. The membrane after the transfer was immobilized by immersing it in a 50% methanol Z 10% acetic acid solution for 5 minutes, and stained with a Rapid Stain CBB Kit (Nakarai) for 20 minutes. Thereafter, the part where PCTF 35 is located is cut out by decolorization and drying, and the amino acid sequencer (HPG 1005A) manufactured by Hulett Packard Co., Ltd. is used to remove the PCTF 35 on the PSQ membrane according to the operation manual of the equipment. The N-terminal amino acid sequence was analyzed. The N-terminal amino acid sequence is shown in FIG.
  • the oligo DNA (sequence 11 below) corresponding to the sequence QQGKE AT, which is a part of the N-terminal 21 residues of PCTF 35 determined in Example 1 (FIG. 9), was designated as SENSE PRIMER.
  • the oligo DNA (the following sequence-2) corresponding to the amino acid sequence YRGRSVP (Fig. 10) at the N-terminus of the limited degradation product of PCTF 35 by bromocyan obtained in 6) was used as an ANTISENSE PRIMER, each of which was manufactured by PE Applied Biosystems. It was synthesized using a DNA synthesizer (AB I 380 B).
  • RNAs to be TA-3 ′ type II were extracted from PC cells using an ISOGEN kit (manufactured by Futatsu Gene) according to the instructions of the kit.
  • a reverse transcription reaction and PCR were carried out using TAKARA RNA PCR kit (AMV) (manufactured by Takara Shuzo Co., Ltd.) under the following conditions using all the RNAs as type II.
  • acrylamide gel electrophoresis (gel concentration: 10%) was performed according to a conventional method, and the gel was stained with ethidium / methylene chloride, and then irradiated with ultraviolet light, and the amplified DNA was located at a position corresponding to about 390 bp. Was confirmed, and a gel containing the band of the amplified DNA was cut out. After homogenizing this gel, add 350 ⁇ L of Maxam Gilbert buffer (0.5 mM ammonium sulfate, 0.1% SDS, 1 mM EDTA, 1 OmM magnesium acetate) and leave at room temperature for 24 hours. After extracting the DNA fragment from, the supernatant was collected by centrifugation at 15000 X g for 10 minutes. The DNA fragment was purified from the recovered supernatant by ethanol precipitation.
  • Maxam Gilbert buffer 0.5 mM ammonium sulfate, 0.1% SDS, 1 mM EDTA, 1 OmM magnesium acetate
  • the amplified DNA purified in 1) was transferred to pBluescriptll (manufactured by Stratagene), a vector sequencing primer, using a Ligation Pack manufactured by Futatsu Gene Co., Ltd. at 16 ° C under the following conditions. The reaction was carried out for 18 hours and ligated to prepare a recombinant vector. Purified amplified DNA 4 ⁇ 1 (200 ng)
  • the entire target gene was obtained by the following RACE (Rapid Amplification of cDNA Ends) method (Frohman. A., et.al., Proc. Natl. Acad. Sci. USA, Vol. 85, p8998 (1988)).
  • sequence 13 was synthesized for 3 ′ RACE, and sequence 14 was synthesized for 5 ′ RACE.
  • agarose gel electrophoresis (gel concentration: 1%) was performed according to a conventional method. The gel was stained with ethidium gel, and then irradiated with ultraviolet light. It was confirmed. Purification of amplified DNA from the gel containing the amplified DNA, integration into a vector, and sequencing were performed in the same manner as in 2) to determine the entire nucleotide sequence of the amplified DNA.
  • the amplified DNA was a DNA consisting of a total of 1,645 bp, and contained a 7 lbp ORF (Open Reading Flame) containing a termination codon in the amplified DNA.
  • the amino acid sequence encoded by this ORF contains the N-terminal amino acid sequence of PCTF 35 and a sequence fragment which partially matches the amino acid sequence at the N-terminus of 23 kd of its limited digest. Therefore, it was determined that the target gene Pctf35 was cloned.
  • SEQ ID NO: 3 shows the entire nucleotide sequence of 1645 bp, which is amplified DNA containing the gene pct35.
  • the amino acid sequence determined from the cloned gene is shown in SEQ ID NO: 3.
  • the N-terminal amino acid sequence of PCTF35 shown in FIG. 9 is the amino acid sequence of the 1st to 22nd amino acids on the N-terminal side of PCTF35: Va1MetGlySerG1y Asp SerVa1ProGlyG1yVa1CysTrpLeuGinGinGlyLysGluAlaThr. It was also found that the N-terminal amino acid sequence shown in FIG. 10 corresponds to the N-terminal 138 to 141st amino acid sequence of PCTF35: TyrArgG1yArg.
  • a recombination vector pcDNA3 (Invitrogen) opened with the restriction enzymes EcoRI and XhoI was prepared, and the recombinant vector pcDNA35 containing the gene pctf35 obtained in Example 2-3) was added. 1 ⁇ g of 645 bp amplified DNA was added, and ligation, transformation and preparation of recombinant DNA were performed in the same manner as in 2) of Example 2 to obtain recombinant expression vector pCTF35.
  • HDMEM containing 3 clones of PC12 / p CTF cells, mock ⁇ PC12 cells, and wild-type PCI2 cells in a Petri dish 10 mm in diameter and 10% horse serum and 5% fetal bovine serum, respectively.
  • Medium (Gibco) Add 1 OmL, culture to 80-90% confluence, and use ISOGEN kit (Futtsubon Gene) and oligotex dT30 (Nippon Synthetic Rubber). mRNA was extracted. 2 / g mRNA was fractionated by agarose gel electrophoresis according to a conventional method, and then transferred to a membrane (NEN Gene Screen Plus) using 10 XSSC buffer at room temperature for 18 hours, followed by Northern hybridization. Was done.
  • a fragment of 1462 bp from the 5 'end of DNA shown in SEQ ID NO: 3 was used as type I and Ramdom Primer DNA Labeling Kit (manufactured by Takara Shuzo) using [ ⁇ -32P] d C
  • a TP-labeled DNA fragment was prepared.
  • Hybridization was carried out at 65 ° C for 16 hours in a solution having the following composition (all concentrations were final concentrations).
  • the membrane was washed twice with 2 XSSC buffer at room temperature for 5 minutes, then with 2 XSSC buffer containing 1% SDS at 60 ° C, twice for 30 minutes, and then with 0.1 XSSC buffer. Using 0.1% SDS at room temperature for 5 minutes once and washing at 51 ° C. Detection of signal after membrane washing is -80. For 24 hours using Hyperfi1m ⁇ -ECL (Amersham) film.
  • Wild type PC12 cells were placed in a 100 mm diameter Petri dish, and 5,000 cells / cm 3 , 10,000 cells cm 3 , 10 mL of serum-free HDMEM medium (Gibco) containing 250 ⁇ g / mL of NGF The cells were added at a cell density of 25,000 cells / cm 3 and cultured for 24 and 48 hours, and the number of viable cells was counted by the trepan pull-one dye exclusion test (Gibco). %.
  • the PC12 / p CTF cells and wild-type PCI2 cells obtained in 1) were 5,000 cells per 10 mL of serum-free HDMEM medium (Gibco) prepared in a Petri dish with a diameter of 10 mm.
  • hpctf35 human homologue of pctf35 obtained in Example 1
  • a part of the nucleotide sequence shown in SEQ ID NO: 3 was pro Brain5'-STRETCH PLUS cDNA Library (manufactured by CLONTECH) was screened.
  • Four hundred positive clones were obtained with a screen jungle of about 500,000 clones. Three of them were found to be genomic fragments, but one was a cDNA fragment containing a poly (A) tail, which partially had high homology with the pctf35 gene.
  • 5'-RACE was performed based on the above sequence.
  • PCR was performed using the ORF region sequence expected to be contained in the previously obtained genomic fragment, and the structure of the hpctf35 gene ORF was determined using the same library and cDNA derived from human placenta. Were determined.
  • the nucleotide sequence of the hpctf35 gene ORF encoding hpctf35 comprising a total of 263 amino acid residues including the signal peptide is shown in SEQ ID NO: 5.
  • the amino acid sequence of hpct35 including the signal peptide deduced therefrom is shown in SEQ ID NO: 4.
  • a protein that suppresses cell death was obtained. Further, according to the present invention, the gene encoding the gene was successfully cloned.
  • the protein for suppressing cell death according to the present invention is useful for treating diseases associated with nerve cell death, and has a function similar to that of the protein, and has an effect of inhibiting or promoting the function of the protein. It is also very useful when developing substances as drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

On décrit une protéine obtenue d'un milieu de culture d'un phéochromocytome transformé par un gène bc12 en tant que protooncogène et pouvant inhiber l'apoptose. On décrit aussi un procédé pour cloner un gène codant ladite protéine. Cette protéine peut contribuer à la mise au point de remèdes contre des maladies provoquées par l'apoptose.
PCT/JP1998/005609 1997-12-12 1998-12-11 Facteur inhibiteur de l'apoptose WO1999031237A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15063/99A AU1506399A (en) 1997-12-12 1998-12-11 Apoptosis inhibitory factor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP34311297 1997-12-12
JP9/343112 1997-12-12
JP10/131634 1998-05-14
JP10131634A JPH11225771A (ja) 1997-12-12 1998-05-14 細胞死抑制因子

Publications (1)

Publication Number Publication Date
WO1999031237A1 true WO1999031237A1 (fr) 1999-06-24

Family

ID=26466414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/005609 WO1999031237A1 (fr) 1997-12-12 1998-12-11 Facteur inhibiteur de l'apoptose

Country Status (3)

Country Link
JP (1) JPH11225771A (fr)
AU (1) AU1506399A (fr)
WO (1) WO1999031237A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372454B2 (en) 1997-08-29 2002-04-16 Human Genome Sciences, Inc. Nucleic acid molecules encoding Follistatin-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF NEUROBIOLOGY, Vol. 25, No. 10, (1994), NOBORU SATO, KAZUHIKO HOTTA et al., "Neuronal Differentiation of PC12 Cells as a Result of Prevention of Cell Death by bcl-2", p. 1227-1234. *
JOURNAL OF NEUROCHEMISTRY, Vol. 69, No. 1, (July 1997), SHEELA VYAS, FRANCE JAVOY-AGID et al., "Expression of Bcl-2 in Adult Human Brain Regions with Special Reference to Neurodegenerative Disorders", p. 223-231. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372454B2 (en) 1997-08-29 2002-04-16 Human Genome Sciences, Inc. Nucleic acid molecules encoding Follistatin-3
US6537966B1 (en) 1997-08-29 2003-03-25 Human Genome Sciences, Inc. Follistatin-3
US6921644B2 (en) 1997-08-29 2005-07-26 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
US7208470B2 (en) 1997-08-29 2007-04-24 Human Genome Sciences, Inc. Method of treating reproductive system cancer by administering follistatin-3
US7595038B2 (en) 1997-08-29 2009-09-29 Human Genome Sciences, Inc. Methods of treatment using antibodies to follistatin-3

Also Published As

Publication number Publication date
JPH11225771A (ja) 1999-08-24
AU1506399A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
JPH11503901A (ja) インターロイキン−１β転換酵素様アポトーシスプロテアーゼ−３および４
JPH07507213A (ja) 消化器デフェンシン，そのｃＤＮＡ配列及び製造方法並びにその使用
JPH06502633A (ja) 気管抗菌ペプチドの生産と用途
Meng et al. Cloning and identification of a novel cDNA coding thioredoxin-related transmembrane protein 2
JP2002165593A (ja) シュードモナス・アエルギノザの外部膜タンパク質ｆ
JP3181660B2 (ja) ビリルビンオキシダーゼの製造法
WO1999031237A1 (fr) Facteur inhibiteur de l'apoptose
US6013473A (en) Human mutY
WO2001012793A1 (fr) Nouvelle desoxyribonuclease, gene codant cette derniere, et procede de production de cette derniere
JP2002085082A (ja) スーパーオキシドジスムターゼ−４
JPH11332571A (ja) 新規遺伝子とそれにコードされる蛋白質
AU751821B2 (en) Saccharide transporter
WO1997033903A1 (fr) MutY D'ORIGINE HUMAINE
JPH10257891A (ja) 神経細胞機能賦活化活性を有する新規蛋白質ｈｕｃｅｐ−１
US6395477B1 (en) Human potassium channel polynucleotide and polypeptides and uses thereof
EP1147192A1 (fr) Polynucleotides et polypeptides humains nogo-c et leurs utilisations
JP4643932B2 (ja) アメロゲニン融合タンパク質
Yamamoto et al. Strong expression of the calreticulin gene in the liver of Rana rugosa tadpoles, but not adult frogs
CN100406559C (zh) 乐昌含笑3-羟基-3-甲基戊二酰辅酶a还原酶蛋白编码序列
US20040092713A1 (en) Novel compounds
JPH1132769A (ja) 新規遺伝子とそれにコードされる蛋白質
US20110200541A1 (en) Recombinant preparation of bromelain inhibitors and bromelain inhibitor precursor
US20040126858A1 (en) Novel polypeptide-nadp dependent leukotriene b412-hydroxydehydrogenase-36 and the polynucleotide encoding said polypeptide
WO1999013074A1 (fr) Proteine activant des fonctions de cellules nerveuses
JPH09157297A (ja) プロテアーゼインヒビター

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA